Oxford Immunotec Global PLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oxford Immunotec Global PLC
What are the skills future life sciences leaders will need in order to rise to the top of biopharma and medtech companies? A recent BioTrinity industry panel debated the profile of tomorrow’s leaders.
Emerging Company Profile: The transatlantic radiopharmaceuticals start-up Theragnostics Ltd. is developing radiotherapeutics and radiodiagnostics for prostate and other cancers.
While a panel of US FDA experts agreed that pathogen reduction technology is a promising strategy for reducing blood platelet contaminations, they raised concerns about the cost of implementing the technology. The maker of the technology, Cerus, says the panel was under-briefed and distracted.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.
- Laboratory Testing Services
- Diagnostic Equipment & Supplies
In Vitro Diagnostics
- Chemistry, Immunoassay
- Other Names / Subsidiaries
- Immunetics, Inc.
- Oxford Immunotec, Inc.
- Oxford Immunotec Ltd.